Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias
The renin-angiotensin-aldosterone system (RAAS) plays a major role in cardiovascular
health and disease. Short-term RAAS activation controls water and salt retention and causes …
health and disease. Short-term RAAS activation controls water and salt retention and causes …
The efficacy and safety of sacubitril/valsartan in heart failure patients: a review
R Zhang, X Sun, Y Li, W He, H Zhu… - Journal of …, 2022 - journals.sagepub.com
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …
Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy
L Maizels, Y Wasserstrum, B Fishman… - ESC Heart …, 2022 - Wiley Online Library
Aims To assess the effect of angiotensin receptor blockers/neprilysin inhibitors (ARNI) on left
ventricular (LV) ejection fraction (LVEF) and LV dimensions in a real‐life cohort of heart …
ventricular (LV) ejection fraction (LVEF) and LV dimensions in a real‐life cohort of heart …
The value of sacubitril/valsartan in acute anterior wall ST-segment elevation myocardial infarction before emergency percutaneous coronary intervention
G Lin, W Chen, M Wu, C Dai, K Xu - Cardiology, 2022 - karger.com
Background: Many patients present with heart failure with reduced ejection fraction (HFrEF)
after acute anterior wall ST-segment elevation myocardial infarction (STEMI). The purpose of …
after acute anterior wall ST-segment elevation myocardial infarction (STEMI). The purpose of …
Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system
BJ Kim, CW Huang, J Chung, JR Neyer, B Liang… - Journal of Managed …, 2022 - jmcp.org
BACKGROUND: Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin
inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme …
inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme …
Estimating the time to benefit for therapies in heart failure with reduced ejection fraction: a case study of sacubitril-valsartan using reconstructed data from a …
L Van der Linden, J Hias, K Walgraeve, J Tournoy… - Drugs & Aging, 2022 - Springer
Background Foundational therapies in heart failure improve clinical outcomes in heart
failure with a reduced ejection fraction (HFrEF). Underuse of these life-prolonging heart …
failure with a reduced ejection fraction (HFrEF). Underuse of these life-prolonging heart …